

Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: December 18, 2024; 9:15a.m. – 1:30 p.m. (Central Time)
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

Attendance

- Members in attendance: Mary Mescher Benbenek, PhD, APRN; Jacques Beasley; Arthur Beisang, MD; Emily Jaeger, PharmD; Kathryn Lombardo, MD; Kelly Ruby, PharmD; Sheila Scheuer, PharmD; Sofia Shrestha, PharmD; Sandra Widhalm Murphy, RPh; Jena Wirt, DO; Margaret Artz, RPh, PhD; Stuart Williams, JD; Monica Brands, RPh
- Members absent: Amirala Pasha, DO, JD; Katherine Montag Schafer, PharmD; Julie Wolfram, DNP, FNP
- DHS staff present: Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Nathan Chomilo, MD; Aaron Drake, RPh
- Others in attendance: Naana Osei-Boateng, PharmD; Chloe Grooms, PharmD; Joshua Williams, PharmD

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- The DFC approved the minutes from the September 2024 meeting with the following amendment under the PDL Review Section:
 - The committee discussed the Glucocorticoids, Inhaled therapeutic class and recommended the following to the department by a unanimous vote:
 - ASMANEX HFA (INHALATION) and QVAR REDHALER (INHALATION) to be moved to the PDL as PREFERRED.
 - FLUTICASONE (FLOVENT DISKUS) (AG) (INHALATION) to be added to the PDL as NONPREFERRED.
 - AEROSPAN (INHALATION), AIRDUO DIGIHALER (INHALATION) *and* ARMONAIR DIGIHALER (INHALATION) *and* ~~ASMANEX HFA (INHALATION)~~ to be removed from the PDL.

DHS Housekeeping

- Election of Chair and Vice Chair
 - The DFC unanimously voted Stuart Williams as Chair of the Committee.

- The DFC unanimously voted Kelly Ruby as Vice Chair of the Committee.
- Update on modernization of pharmacy claims processing system: DHS shared that the implementation of the new point-of-sale system overall has been positive. DFC member feedback was solicited.

Old Business

- DHS advised the committee that Dexcom now offers a program allowing same day replacement of their CGM products for MN Medicaid members.
- The DFC has posted vacancies on the MN Secretary of State webpage. The Committee seeks to recruit a license pediatrician and a licensed pharmacist to join the committee.

New Business

Existing Specialty Drugs for Continued PA

- The DFC reviewed and unanimously voted to approve the updates to Oncology drugs PA criteria with the following amendment: the removal of sub sub bullet under fourth bullet point under the approval criteria section.
 - An indication that is consistent with NCCN (National Comprehensive Cancer Network) recommendation with a level of evidence of Category 1 or 2A.
 - ~~If there are more than one recommended drug in Category 1 or 2A, prescriber provides a clinical rationale for the requested drug; OR~~
- The DFC reviewed and unanimously voted to approve the updates to Leqembi PA criteria.

Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed Kisunla and recommended to DHS by a unanimous vote that Kisunla remain on PA with the proposed criteria.
- The committee discussed Ravicti and recommended to DHS by a unanimous vote that Ravicti remain on PA with the proposed criteria:
- The committee discussed Iqirvo and recommended to DHS by a unanimous vote that Iqirvo remain on PA with the proposed criteria.
- The committee discussed Livdelzi and recommended to DHS by a unanimous vote that Livdelzi remain on PA with the proposed criteria.

- The committee discussed Piasky and recommended to DHS by a unanimous vote that Piasky remain on PA with the proposed criteria:

Preferred Drug List (PDL) Review

- The committee discussed the Angiotensin Modulators therapeutic class and recommended the following to the department by a unanimous vote:
 - ENTRESTO SPRINKLE CAP (ORAL) to be added to the PDL as NONPREFERRED
 - TEKTRINA HCT (ORAL) and ACCUPRIL (ORAL) to be removed from the PDL.
- The committee discussed the Antidepressants, Other therapeutic class and recommended the following to the department by a unanimous vote:
 - DESVENLAFAXINE ER (NO BRAND) (ORAL) and DESVENLAFAXINE ER (PRISTIQ) (ORAL) to be moved to PREFERRED on the PDL.
 - ZURZUVAE (ORAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Antipsychotics therapeutic class and recommended the following to the department by a unanimous vote:
 - PALIPERIDONE (ORAL) to be moved to PREFERRED on the PDL.
 - COBENFY (ORAL) to be added to the PDL as NONPREFERRED.
 - PERSERIS (SUBCUTANE.) to be removed from the PDL.
- The committee discussed the COPD Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - OHTUVAYRE (INHALATION) to be added to the PDL as NONPREFERRED.
- The committee discussed the Diabetes Meters therapeutic class (a new class to the PDL) and recommended the following to the department by a unanimous vote:
 - ACCU-CHEK AVIVA PLUS, CONTOUR NEXT and CONTOUR NEXT GEN to be moved to NONPREFERRED on the PDL.
 - ACCU-CHEK NANO SMARTVIEW to be removed from the PDL.
- The committee discussed the Diabetes Test Strips therapeutic class and recommended the following to the department by a unanimous vote:
 - ACCU-CHEK COMPACT PLUS to be removed from the PDL.

- The committee discussed the Lipotropics, Statins therapeutic class and recommended the following to the department by a unanimous vote:
 - FLOLIPID SUSPENSION (ORAL) and PITAVASTATIN CALCIUM (ORAL) to be added to the PDL as NONPREFERRED
 - CRESTOR (ORAL) to be removed from the PDL.

- The committee discussed the Phosphate Binders therapeutic class and recommended the following to the department by a unanimous vote:
 - SEVELAMER CARBONATE POWDER PACK (ORAL) to be moved to PREFERRED on the PDL.
 - RENVELA POWDER PACK (ORAL) to be moved to NONPREFERRED on the PDL.
 - XPHOZAH TABLET (ORAL) to be added to the PDL as NONPREFERRED.

CONSENT AGENDA ITEMS:

The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be passed as presented with no changes.

Other Business

- DHS acknowledged and thanked the DFC for their service and commitment.

Adjournment

- The meeting was adjourned at approximately 11:42am Central Time.